R

Ryvu Therapeutics SA
WSE:RVU

Watchlist Manager
Ryvu Therapeutics SA
WSE:RVU
Watchlist
Price: 26.45 PLN -1.67% Market Closed
Market Cap: zł611.5m

Relative Value

The Relative Value of one RVU stock under the Base Case scenario is hidden PLN. Compared to the current market price of 26.45 PLN, Ryvu Therapeutics SA is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

RVU Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

RVU Competitors Multiples
Ryvu Therapeutics SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
PL
Ryvu Therapeutics SA
WSE:RVU
621.9m PLN 9 -5.3 -5 -4.5
US
PerkinElmer Inc
LSE:0KHE
1.3T USD 460.4 5 453.9 1 599.2 3 212.8
US
Thermo Fisher Scientific Inc
NYSE:TMO
238.1B USD 5.4 36.2 25.6 33.1
US
Danaher Corp
NYSE:DHR
167.3B USD 6.9 47.8 25.6 38.6
KR
Samsung Biologics Co Ltd
KRX:207940
83.6T KRW 15.1 52.2 30.7 40.9
CH
Lonza Group AG
SIX:LONN
37.8B CHF 5.4 52.1 39.3 39.3
US
IQVIA Holdings Inc
NYSE:IQV
40.5B USD 2.5 31.6 15.2 22.7
CN
WuXi AppTec Co Ltd
SSE:603259
277.8B CNY 6.3 18.6 18.7 18.7
US
Agilent Technologies Inc
NYSE:A
38.4B USD 5.5 29.6 22.9 27.3
US
Mettler-Toledo International Inc
NYSE:MTD
29.1B USD 7.4 34.9 25.1 27.9
FR
Sartorius Stedim Biotech SA
PAR:DIM
20.3B EUR 6.9 77.3 27.3 44.9
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
PL
R
Ryvu Therapeutics SA
WSE:RVU
Average EV/EBITDA: 183
Negative Multiple: -5
N/A N/A
US
P
PerkinElmer Inc
LSE:0KHE
1 599.2
5%
319.8
US
Thermo Fisher Scientific Inc
NYSE:TMO
25.6
6%
4.3
US
Danaher Corp
NYSE:DHR
25.6
5%
5.1
KR
Samsung Biologics Co Ltd
KRX:207940
30.7
20%
1.5
CH
Lonza Group AG
SIX:LONN
39.3
18%
2.2
US
IQVIA Holdings Inc
NYSE:IQV
15.2
8%
1.9
CN
WuXi AppTec Co Ltd
SSE:603259
18.7
30%
0.6
US
Agilent Technologies Inc
NYSE:A
22.9
14%
1.6
US
Mettler-Toledo International Inc
NYSE:MTD
25.1
4%
6.3
FR
Sartorius Stedim Biotech SA
PAR:DIM
27.3
19%
1.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
PL
R
Ryvu Therapeutics SA
WSE:RVU
Average EV/EBIT: 350.6
Negative Multiple: -4.5
N/A N/A
US
P
PerkinElmer Inc
LSE:0KHE
3 212.8
29%
110.8
US
Thermo Fisher Scientific Inc
NYSE:TMO
33.1
15%
2.2
US
Danaher Corp
NYSE:DHR
38.6
16%
2.4
KR
Samsung Biologics Co Ltd
KRX:207940
40.9
28%
1.5
CH
Lonza Group AG
SIX:LONN
39.3
22%
1.8
US
IQVIA Holdings Inc
NYSE:IQV
22.7
14%
1.6
CN
WuXi AppTec Co Ltd
SSE:603259
18.7
23%
0.8
US
Agilent Technologies Inc
NYSE:A
27.3
22%
1.2
US
Mettler-Toledo International Inc
NYSE:MTD
27.9
6%
4.6
FR
Sartorius Stedim Biotech SA
PAR:DIM
44.9
31%
1.4